Hong Kong stock eccentric movement | Boan Biotech (06955.HK) surges over 4% as Nasimirumab China Phase III clinical trial completes all patient enrollments

According to the Zhutong Financial APP, Boran Biotech (06955.HK) rose by more than 4%. As of the time of writing, it has increased by 3.46% to 10.48 Hong Kong dollars, with a trading volume of 45.9821 million Hong Kong dollars.